Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Macroeconomic Indicators
4.5 Pipeline Products
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Fabry Disease Market, by Type
6.1 Introduction
6.2 Type 1 Fabry Disease
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3 Type 2 Fabry Disease
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 7. Global Fabry Disease Market, by Diagnosis & Treatment
7.1 Introduction
7.2 Diagnosis
7.2.1 Blood Test
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.2 Urine Test
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.3 Thyroid Test
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.4 Lung Function Test
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.5 Imaging
7.2.5.1 Electrocardiogram (EKG)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.5.2 Echocardiogram
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.5.3 Brain MRI
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.5.4 CT Scan
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.5.5 Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.6 Hearing and Eye Examination
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.7 Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3 Treatment
7.3.1 Enzyme Replacement Therapy
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.2 Gene Therapy
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.3 Pharmaceutical Formulations Containing Agalsidase Alfa
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.4 Analgesics
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.5 Anticonvulsants
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.6 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.7 Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 8. Global Fabry Disease Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.3 Diagnostic Centers
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.4 Research & Academic Institutes
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.5 Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 9. Global Fabry Disease Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
Chapter 11. Company Profiles
11.1 AMGEN INC.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 AMICUS THERAPEUTICS, INC.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 BRISTOL-MYERS SQUIBB COMPANY
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 GlaxoSmithKline
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 IBio, Inc.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Neuraltus Pharmaceuticals, Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Novartis AG
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 PFIZER INC.
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Sanofi
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Shire
11.10.1 Overview
11.10.2 Product Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Takeda Pharmaceutical Company Limited
11.11.1 Overview
11.11.2 Product Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Teva Pharmaceutical Industries Ltd
11.12.1 Overview
11.12.2 Product Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 AVROBIO, Inc.
11.13.1 Overview
11.13.2 Product Overview
11.13.3 Financials
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.14 Idorsia Pharmaceuticals Ltd
11.14.1 Overview
11.14.2 Product Overview
11.14.3 Financials
11.14.4 Key Developments
11.14.5 SWOT Analysis
11.15 Protalix
11.15.1 Overview
11.15.2 Product Overview
11.15.3 Financials
11.15.4 Key Developments
11.15.5 SWOT Analysis
11.16 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Predictions for the Fabry Disease Industry
Chapter 13 Appendix
LIST OF TABLES
Table 1 Global Fabry Disease Market Synopsis, 2023-2030
Table 2 Global Fabry Disease Market Estimates and Forecast, 2023-2030 (USD Million)
Table 3 Global Fabry Disease Market, by Region, 2023-2030 (USD Million)
Table 4 Global Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 5 Global Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 6 Global Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 7 North America: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 8 North America: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 9 North America: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 10 US: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 11 US: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 12 US: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 13 Canada: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 14 Canada: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 15 Canada: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 16 South America: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 17 South America: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 18 South America: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 19 Europe: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 20 Europe: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 21 Europe: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 22 Western Europe: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 23 Western Europe: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 24 Western Europe: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 25 Eastern Europe: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 26 Eastern Europe: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 27 Eastern Europe: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 28 Asia-Pacific: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 29 Asia-Pacific: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 30 Asia-Pacific: Fabry Disease Market, by End User, 2023-2030 (USD Million)
Table 31 Middle East & Africa: Fabry Disease Market, by Type, 2023-2030 (USD Million)
Table 32 Middle East & Africa: Fabry Disease Market, by Diagnosis & Treatment, 2023-2030 (USD Million)
Table 33 Middle East & Africa: Fabry Disease Market, by End User, 2023-2030 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Market Structure for Global Fabry Disease Market
Figure 3 Market Dynamics for Global Fabry Disease Market
Figure 4 Global Fabry Disease Market Share, by Type, 2023
Figure 5 Global Fabry Disease Market Share, by Diagnosis & Treatment, 2023
Figure 6 Global Fabry Disease Market Share, by End User, 2023
Figure 7 Global Fabry Disease Market Share, by Region, 2023
Figure 8 North America: Fabry Disease Market Share, by Country, 2023
Figure 9 Europe: Fabry Disease Market Share, by Country, 2023
Figure 10 Asia-Pacific: Fabry Disease Market Share, by Country, 2023
Figure 11 Middle East & Africa: Fabry Disease Market Share, by Country, 2023
Figure 12 Global Fabry Disease Market: Company Share Analysis, 2023 (%)
Figure 13 AMGEN INC.: Key Financials
Figure 14 AMGEN INC.: Segmental Revenue
Figure 15 AMGEN INC.: Geographical Revenue
Figure 16 AMICUS THERAPEUTICS, INC.: Key Financials
Figure 17 AMICUS THERAPEUTICS, INC.: Segmental Revenue
Figure 18 AMICUS THERAPEUTICS, INC.: Geographical Revenue
Figure 19 BRISTOL-MYERS SQUIBB COMPANY: Key Financials
Figure 20 BRISTOL-MYERS SQUIBB COMPANY: Segmental Revenue
Figure 21 BRISTOL-MYERS SQUIBB COMPANY: Geographical Revenue
Figure 22 GlaxoSmithKline: Key Financials
Figure 23 GlaxoSmithKline: Segmental Revenue
Figure 24 GlaxoSmithKline: Geographical Revenue
Figure 25 IBio, Inc.: Key Financials
Figure 26 IBio, Inc.: Segmental Revenue
Figure 27 IBio, Inc.: Geographical Revenue
Figure 28 Neuraltus Pharmaceuticals, Inc.: Key Financials
Figure 29 Neuraltus Pharmaceuticals, Inc.: Segmental Revenue
Figure 30 Neuraltus Pharmaceuticals, Inc.: Geographical Revenue
Figure 31 Novartis AG: Key Financials
Figure 32 Novartis AG: Segmental Revenue
Figure 33 Novartis AG: Geographical Revenue
Figure 34 PFIZER INC.: Key Financials
Figure 35 PFIZER INC.: Segmental Revenue
Figure 36 PFIZER INC.: Geographical Revenue
Figure 37 Sanofi: Key Financials
Figure 38 Sanofi: Segmental Revenue
Figure 39 Sanofi: Geographical Revenue
Figure 40 Shire: Key Financials
Figure 41 Shire: Segmental Revenue
Figure 42 Shire: Geographical Revenue
Figure 43 Takeda Pharmaceutical Company Limited: Key Financials
Figure 44 Takeda Pharmaceutical Company Limited: Segmental Revenue
Figure 45 Takeda Pharmaceutical Company Limited: Geographical Revenue
Figure 46 Teva Pharmaceutical Industries Ltd: Key Financials
Figure 47 Teva Pharmaceutical Industries Ltd: Segmental Revenue
Figure 48 Teva Pharmaceutical Industries Ltd: Geographical Revenue
Figure 49 AVROBIO, Inc.: Key Financials
Figure 50 AVROBIO, Inc.: Segmental Revenue
Figure 51 AVROBIO, Inc.: Geographical Revenue
Figure 52 Idorsia Pharmaceuticals Ltd: Key Financials
Figure 53 Idorsia Pharmaceuticals Ltd: Segmental Revenue
Figure 54 Idorsia Pharmaceuticals Ltd: Geographical Revenue
Figure 55 Protalix: Key Financials
Figure 56 Protalix: Segmental Revenue
Figure 57 Protalix: Geographical Revenue
